VSIR and melanoma: So far, studies evaluating the immunohistochemistry expression of VISTA in patients with melanoma have concluded that its positivity is associated with poor survival, by contributing to immune suppression and evading immune surveillance; therefore, it negatively impacts the prognosis [18,19,20].